PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
83.07%
Net income growth under 50% of CRON.TO's 542.15%. Michael Burry would suspect deeper structural issues in generating bottom-line growth.
-4.44%
Both reduce yoy D&A, with CRON.TO at -101.29%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
No Data
No Data available this quarter, please select a different quarter.
-30.73%
Negative yoy SBC while CRON.TO is 0.00%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
71.96%
Less working capital growth vs. CRON.TO's 696.76%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
No Data
No Data available this quarter, please select a different quarter.
-216.44%
Negative yoy inventory while CRON.TO is 0.00%. Joel Greenblatt would see a near-term cash advantage if top-line doesn't suffer.
No Data
No Data available this quarter, please select a different quarter.
132.10%
Lower 'other working capital' growth vs. CRON.TO's 1775.82%. David Dodd would see fewer unexpected short-term demands on cash.
-111.05%
Both negative yoy, with CRON.TO at -2303.40%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
54.66%
Operating cash flow growth below 50% of CRON.TO's 176.96%. Michael Burry would see a serious shortfall in day-to-day cash profitability.
-41.50%
Both yoy lines negative, with CRON.TO at -156.40%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
-99.33%
Both yoy lines negative, with CRON.TO at -100.00%. Martin Whitman sees an overall caution or integration phase for both companies’ expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-48279507710815.58%
We reduce yoy other investing while CRON.TO is 0.00%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
-273.24%
Both yoy lines negative, with CRON.TO at -964.00%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
-98.99%
Negative yoy issuance while CRON.TO is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.